Late-Breaking Trials

Late-Breaking Clinical Trials & Clinical Science

Program Information

Showcase the latest in Science, Technology, and Research

Share impactful research to improve the field of interventional cardiology! Present and discuss innovative studies that highlight the latest breakthroughs in science and enhancements to quality patient care and significantly impact the field of interventional cardiology at CRT 2024.

Late-Breaking Trial Submission Deadline: Submissions have closed.

Experience 39 Presentations of Key Clinical Trials and Significant Research at CRT 2024, See This Year’s Full List:

Saturday, March 9, 2024  
Late-Breaking Clinical Trials – Drug Coated Balloon & Pharma  
2:00 PM – 3:15 PM  

Paclitaxel-Coated Balloon Versus Uncoated Balloon for Coronary In-Stent Restenosis – Primary Outcomes from the Full Population of the AGENT IDE Trial
Speaker: Robert Yeh

Drug-Coated Balloons vs Drug-Eluting Stents or Plain Old Balloon Angioplasty for In-Stent Restenosis: A Nationwide Segment-Level Analysis from SCAAR of 7987 Patients
Speaker: David Erlinge

Assessment of Long-Term Clinical Outcomes of De Novo DCB Performance: A Comprehensive, Individual Patient Data Meta-Analysis of Randomized Clinical Trials: The Andromeda Study
Speaker: Bernardo Cortese

Ticagrelor Monotherapy in Patients with Acute Coronary Syndrome: An Individual Patient Data Meta-Analysis of Randomized TICO and T-PASS Trials
Speaker: Myeong-Ki Hong

Saturday, March 9, 2024  
Late-Breaking Clinical Science – Intravascular Imaging / Physiology  
3:15 PM – 4:30 PM  

IVUS Use and Long-Term PCI Outcomes in the United States: Insights from the Premier Database
Speaker: Laith Derbas

Fractional Flow Reserve or Optical Coherence Tomography to Guide the Management of Patients with Angiographically Intermediate Coronary Stenosis: 5-Year Clinical Outcomes Observed in the FORZA Trial
Speaker: Francesco Burzotta

Safety and Efficacy of the Xience Everolimus-Eluting Stent for Treatment of In-Stent Restenosis – An ILUMIEN IV Substudy
Speaker: Ziad Ali

Physiological Performance of Drug-Coated Balloons or Drug-Eluting Stents in Small Coronary Arteries: The PICCOLETO II UFR Study
Speaker: Bernardo Cortese

Coronary Plaque Size Changes Can Be Predicted by Using a Deep-Learning Model: An IVUS Study with External Validation
Speaker: Hector Garcia-Garcia

Sunday, March 10, 2024  
Late-Breaking Clinical Trials – Coronary CABG / PCI  
2:00 PM – 3:15 PM  

The Association of Socioeconomic Status with Procedural Management and Mortality After Percutaneous Coronary Intervention: An Observational Study from the Pan-London PCI Registry
Speaker: Krishnaraj Rathod

Computed Tomography Cardiac Angiography Prior to Invasive Coronary Angiography in Patients with Previous Bypass Surgery: Patient-Related Outcomes, Imaging Resource Utilisation, and Long-Term Cardiac Events from the BYPASS-CTCA Trial
Speaker: Matthew Kelham

The Safe Surveillance of Percutaneous Coronary Intervention Under Mechanical Circulatory Support with the Saranas Early Bird Bleeding Monitoring System (SAFE-MCS) Study
Speaker: Babar Basir

Time-Dependent Outcomes with the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-Up: Final Report from the ABSORB Trial Program
Speaker: David Power

Immediate Versus Staged Complete Revascularization in Patients Presenting with Acute Coronary Syndrome and Multivessel Coronary Disease: 2-Year Follow-Up of the Multicentre Randomized Controlled BIOVASC Trial
Speaker: Roberto Diletti

Sunday, March 10, 2024  
Late-Breaking Early Feasibility Study Clinical Trials   
3:15 PM – 4:30 PM  

SESAME Transcatheter Myotomy: The Emory Experience
Speaker: Vasilis Babaliaros

DurAVR Biomimetic Transcatheter Heart Valve: Early Feasibility Study (EFS) Update
Speaker: Christopher Meduri

Transcatheter Treatment of Chronic Aortic Regurgitation with a Novel Device: Results of J-Valve Transfemoral Early Feasibility Study (JVTF EFS)
Speaker: Dean Kereiakes

TAVR Designs for Non-Calcific Regurgitation and Calcific Stenosis – The Laguna Tech Solution
Speaker: Scott Lim

Three-Dimension Intracardiac (3D-ICE) vs Transesophageal (TEE) Echocardiography to Guide Transcatheter Edge-to-Edge Repair (TEER) With MitraClip: Interim Results of the 3 Dice-Clip Trial
Speaker: Fadi Matar

VELAZQUEZ EPIC26 Study: ihtDEStiny® Coronary Stent
Speaker: Armando Perez de Prado

Monday, March 11, 2024  
Late-Breaking Artificial Intelligence Clinical Trials  
8:00 AM – 9:00 AM  

Artificial Intelligence-Derived Automated Intravascular Ultrasound-Based Calcium Score to Predict Stent (Under-)Expansion in Severely Calcified Lesions
Speaker: Saurav Chatterjee

Artificial Intelligence System for Identifying and Notifying Hazardous Situations in the Catheterization Laboratory
Speaker: Yair Feld

ECGio – An AI Algorithm to Predict the Presence and Severity of Flow-Limiting CAD Using a Standard 12-Lead ECG
Speaker: Michael Leasure

4TAVR - A Fully Automated Cloud-Based AI-Driven Pre-Procedural TAVR Planning Software
Speaker: Moritz Wyler von Ballmoos

Monday, March 11, 2024  
Late-Breaking Clinical Trials – Structural / LAA  
11:40 AM – 12:40 PM  

Five-Year Durability and Performance Evaluation of an Intra-Annular, Self-Expanding Transcatheter Heart Valve
Speaker: Rishi Puri

Cost-Effectiveness of Transcatheter Aortic Valve Replacement for Low-Risk Patients – Updated Results from the Evolut Low Risk Trial
Speaker: David Cohen

One-Year Outcomes in the Navitor IDE Study Utilizing the Intra-Annular, Self-Expandable Navitor Transcatheter Aortic Heart Valve
Speaker: Paul Mahoney

Learning Curve and Outcomes with the Amulet Occluder Within the Emerge LAA Post-Approval Study
Speaker: Atman Shah

Monday, March 11, 2024  
Late Breaking Clinical Science – Structural / LAA  
2:00 PM – 3:30 PM  

Valve Size, Transvalvular Pressure Gradients, and Mortality Following Transcatheter Aortic Valve Replacement with Balloon-Expandable Valves
Speaker: Amr Abbas

AltaValve Atrial Fixation TMVR Early Feasibility Study Results
Speaker: Vlasis Ninios

Performance of Purpose-Built Versus Off-Label Transcatheter Devices for the Treatment of Aortic Regurgitation: The Purpose Study
Speaker: Luca Testa

Multivalvular Heart Disease in TAVR Patients: A Multicenter Study Assessing the Impact of Staged Valvular Interventions on Outcomes
Speaker: Baravan Al-Kassou

Surgical Aortic Valve Replacement with Contemporary Valves Versus Self-Expanding Transcatheter Aortic Valve Replacement: 4-Year Outcomes from the Evolut Low Risk Trial
Speaker: Basel Ramlawi

Cerebral Embolic Protection Device in Transcatheter Aortic Valve Replacement Associated with Increased Risk For Hemorrhagic Stroke
Speaker: Ibrahim Ahmed

Tuesday, March 12, 2024  
Late-Breaking Clinical Science – Hot Topics  
8:00 AM – 9:10 AM  

Benefits of Dynamx Bioadaptor Versus DES in Patients With Dyslipidemia: Subgroup Analysis Results from the BIOADAPTOR RCT
Speaker: Shigeru Saito

Comprehensive Radiation Shield Minimizes Operator Radiation Exposure in Coronary and Structural Heart Procedures
Speaker: David Rizik

The Association Between Diagnosis-to-Limb Revascularization Time and Clinical Outcomes in Outpatients with Chronic Limb-Threatening Ischemia: Insights From the CLIPPER Cohort
Speaker: Alexander Fanaroff

A Blood Biomarker-Based Diagnosis of Reperfused Hemorrhagic ST-Elevation Myocardial Infarction Predicts Acute Outcomes
Speaker: Ankur Kalra

CT-Guided Ozone-Mediated Renal Denervation Treating Resistant Hypertension
Speaker: Li Li

Recognition:

In addition to exposure among colleagues, selected Late-Breaking Trial presenters will be CRT 2024 Associate Faculty. As Associate Faculty, your CRT 2024 registration fee will be waived, you will receive a complimentary subscription to Cardiovascular Revascularization Medicine, complimentary access to CRT Premium and access to the Faculty Lounge at the Washington Hilton Hotel.

Submission Details:

CRT 2024 Late-Breaking Trials are expected to contain the study design, baseline characteristics of the patients enrolled, and trial results. Examples of Late-Breaking Trials include primary results from randomized controlled trials; subgroup analyses, post hoc or prespecified, and long-term follow-up results of randomized trials; observational studies of devices or treatments; and meta-analyses of multiple studies.

One application must be submitted for each Late-Breaking Trial.
Please include Late-Breaking Trial submissions and supporting files in the following formats: Word, PowerPoint, Excel or PDF.
Please use the CRT 2024 PPT Template submit your Late-Breaking Trial.
You will have the opportunity to upload more than one file. It may take several minutes for larger files to load.
Files must be 20 MB or smaller.
Presentations of accepted Late-Breaking Trials prior to CRT 2024 are strictly prohibited.
Submissions may not be withdrawn for negative results, and such actions will negatively affect future Late-Breaking Trial applications from both the applicant and the trial sponsor.
A submission indicates that the trial results will be available by CRT 2024.
Accepted trials will be presented in the Main Arena with the exact date and times to be determined.

Late-Breaking Trials must be submitted electronically by 5:00 PM ET on Tuesday, January 16, 2024.

Inquiries: If you have any questions, please email submissions@crtmeeting.org.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Late-Breaking Clinical Trials & Clinical Science

Program Information

Experience 39 Presentations of Key Clinical Trials and Significant Research at CRT 2024, See This Year’s Full List:

Recognition:

Submission Details: